In a deal potentially worth $810 million for Regenxbio Inc., Nippon Shinyaku Co. Ltd. is partnering on the U.S. and Asian development and commercialization of iduronate-2-sulfatase enzyme RGX-121 for ...
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the ...
An experimental tuberculosis (TB) vaccine with a dual mission – self-destruction after inducing immunity – improved the design of the Bacillus Calmette-Guérin (BCG) immunotherapy, a vaccine also used ...
Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...
Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback